Cargando…

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

BACKGROUND: Patients with cognitive impairment associated with schizophrenia may benefit from treatments targeting dysfunctional glutamatergic neurotransmission. BI 409306, a potent and selective phosphodiesterase 9 inhibitor, was assessed in patients with schizophrenia using a learn-and-confirm ada...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, David, Nakagome, Kazuyuki, Cordes, Joachim, Brenner, Ronald, Gründer, Gerhard, Keefe, Richard S E, Riesenberg, Robert, Walling, David P, Daniels, Kristen, Wang, Lara, McGinniss, Jennifer, Sand, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403090/ https://www.ncbi.nlm.nih.gov/pubmed/29718385 http://dx.doi.org/10.1093/schbul/sby049

Ejemplares similares

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia
por: Brown, David, et al.
Publicado: (2017)

Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders
por: Scarborough, Joseph, et al.
Publicado: (2021)

First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
por: Moschetti, Viktoria, et al.
Publicado: (2016)

A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale
por: Keefe, Richard S. E., et al.
Publicado: (2020)

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study
por: Müller, Fabian, et al.
Publicado: (2022)

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease
por: Frölich, Lutz, et al.
Publicado: (2019)

Cómo se vende un presidente /
por: McGinniss, Joe
Publicado: (1974)

Cómo se vende un presidente /
por: McGinniss, Joe
Publicado: (1970)

Shifting the Overton Window on Nontuberculous Mycobacterial Disease Infection Susceptibility by Race
por: McGinniss, John E.
Publicado: (2023)

The Upper Airway Microbiome and Lung Injury in COVID-19
por: McGinniss, John E., et al.
Publicado: (2021)

Tracer Exchange vs. Net Uptake of Glucose through Human Red Cell Surface : New evidence for carrier-mediated diffusion
por: LeFevre, P. G., et al.
Publicado: (1960)

Musculoskeletal Imaging for Low Back Pain in Direct Access Physical Therapy Compared to Primary Care: An Observational Study
por: Crowell, Michael S, et al.
Publicado: (2022)

Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms
por: Umbricht, Daniel, et al.
Publicado: (2021)

Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2014)

Multiple Property Tolerance Analysis for the Evaluation of Missense Mutations
por: Lee, Tai-Sung, et al.
Publicado: (2007)

Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2013)

Association of fronto-temporal function with cognitive ability in schizophrenia
por: Pu, Shenghong, et al.
Publicado: (2017)

The Effect of Blood Flow Restriction Therapy on Shoulder Function Following Shoulder Stabilization Surgery: A Case Series
por: McGinniss, John H., et al.
Publicado: (2022)

Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders
por: Cohen, Elan A., et al.
Publicado: (2020)

Neural Correlates for Intrinsic Motivational Deficits of Schizophrenia; Implications for Therapeutics of Cognitive Impairment
por: Takeda, Kazuyoshi, et al.
Publicado: (2018)

Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia
por: Kossmann, C., et al.
Publicado: (2020)

Associations between depressive symptoms and fronto-temporal activities during a verbal fluency task in patients with schizophrenia
por: Pu, Shenghong, et al.
Publicado: (2016)

Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2022)

T66. PSYCHOMETRIC VALIDATION OF A NOVEL PATIENT-REPORTED OUTCOME MEASURE FOR ASSESSING PATIENTS’ SUBJECTIVE EXPERIENCE OF COGNITIVE IMPAIRMENT OF SCHIZOPHRENIA (PRECIS)
por: Rosen, Raymond, et al.
Publicado: (2018)

Correction to: Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia
por: Kossmann, C., et al.
Publicado: (2022)

PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
por: Riesenberg, Robert, et al.
Publicado: (2020)

Right Frontotemporal Cortex Mediates the Relationship between Cognitive Insight and Subjective Quality of Life in Patients with Schizophrenia
por: Pu, Shenghong, et al.
Publicado: (2018)

Modification of a bi-functional diguanylate cyclase-phosphodiesterase to efficiently produce cyclic diguanylate monophosphate
por: Nesbitt, Natasha M., et al.
Publicado: (2015)

Neurocognitive features in male patients with schizophrenia exhibiting serious violence: a case control study
por: Kashiwagi, Hiroko, et al.
Publicado: (2015)

4167 Peri-transplant Lung Microbiome Reveal Oral Bacteria, Pepsin And Inflammatory Markers Co-associate With Primary Graft Dysfunction, Implicating Aspiration As A Potential Contributor
por: McGinniss, John Evan, et al.
Publicado: (2020)

Impaired prefrontal activity to regulate the intrinsic motivation-action link in schizophrenia
por: Takeda, Kazuyoshi, et al.
Publicado: (2017)

Phosphodiesterase-5 Inhibitors for Premature Ejaculation: Systematic Review and Meta-Analysis of Placebo-Controlled Trials
por: Zhang, Xuebao, et al.
Publicado: (2020)

A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan
por: Higuchi, Teruhiko, et al.
Publicado: (2016)

Two Phosphodiesterases from Ustilago Maydis Share Structural and Biochemical Properties with Non-Fungal Phosphodiesterases
por: Agarwal, Charu, et al.
Publicado: (2010)

THU402 New Heterotopic Ossification Lesions In Patients With Fibrodysplasia Ossificans Progressiva Measured By PET/CT vs CT Only
por: Trotter, Dinko Gonzalez, et al.
Publicado: (2023)

Compassionate Use of REGEN-COV(®) in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders
por: Stein, David, et al.
Publicado: (2021)

Involvement and Possible Role of Eosinophils in Asthma Exacerbation
por: Nakagome, Kazuyuki, et al.
Publicado: (2018)

Possible Mechanisms of Eosinophil Accumulation in Eosinophilic Pneumonia
por: Nakagome, Kazuyuki, et al.
Publicado: (2020)

Allergen Immunotherapy in Asthma
por: Nakagome, Kazuyuki, et al.
Publicado: (2021)

Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation
por: Nakagome, Kazuyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5bm6ji0dhlq19v9k05hl54n7ai